Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
2(18%)
Results Posted
33%(2 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_3
2
18%
Ph not_applicable
2
18%
Ph phase_1
1
9%
Ph phase_2
3
27%
Ph phase_4
2
18%

Phase Distribution

1

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
2(20.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(6)
Terminated(1)
Other(2)

Detailed Status

Completed6
unknown2
Recruiting1
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 23 (30.0%)
Phase 32 (20.0%)
Phase 42 (20.0%)
N/A2 (20.0%)

Trials by Status

unknown218%
completed655%
recruiting19%
terminated19%
active_not_recruiting19%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
DRUG
Total Trials
11